Repatha Cost in Hawaii 2026: Price, Insurance, Medicaid, and Compounding Options

What Does Repatha Actually Cost in Hawaii Right Now?

The Amgen wholesale acquisition cost for evolocumab in Hawaii is $580 per month as of 2026, regardless of whether a patient uses the 140 mg biweekly or the 420 mg monthly regimen. That figure is the starting point for every pricing conversation, but very few patients actually pay it. What you pay depends on your insurance tier, your eligibility for manufacturer assistance, and whether your clinician writes a prescription for a compounded formulation instead.

Retail pharmacy cash prices at Hawaii chains, including Longs Drugs locations operated by CVS and independent pharmacies in Honolulu, Hilo, and Kailua-Kona, track closely to the $580 WAC because no generic evolocumab exists and biosimilar competition for this molecule remains limited in the United States as of early 2026. The FDA has not yet approved a biosimilar evolocumab; inclisiran (Leqvio), a small interfering RNA PCSK9 inhibitor, is a separate drug class approved in 2021, not a direct substitute [1].

Patients with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) typically qualify for evolocumab after demonstrating inadequate LDL-C control on maximally tolerated statin therapy plus ezetimibe. The 2022 ACC/AHA Guideline on the Management of Patients with Chronic Coronary Disease recommends PCSK9 inhibitors when LDL-C remains above 70 mg/dL despite optimized oral therapy [2]. Hawaii prescribers, including cardiologists at Queen's Medical Center in Honolulu and telehealth clinicians serving neighbor islands, follow these same national thresholds.

Does Hawaii Medicaid Cover Repatha?

Hawaii Medicaid (Med-QUEST) does not cover Repatha as of 2026. This is a significant barrier. Approximately 23% of Hawaii residents are enrolled in Med-QUEST or CHIP [3], meaning a large share of the state's high-cardiovascular-risk population has no publicly funded pathway to brand-name evolocumab.

Hawaii Med-QUEST managed care plans, including 'Ohana Health Plan, UnitedHealthcare Community Plan Hawaii, and Kaiser Permanente Hawaii Medicaid, mirror the state formulary exclusion. Prior authorization requests for evolocumab under Medicaid have historically been denied at the plan level statewide. The ACC/AHA 2019 Primary Prevention Guideline explicitly notes that cost and access remain the "most frequent barriers to PCSK9 inhibitor use" in real-world practice [4].

For Medicaid patients, practical alternatives include maximizing ezetimibe (which reduces LDL-C by approximately 18 to 24% [5]) and bempedoic acid (Nexletol), which the FDA approved in 2020 and which some Med-QUEST plans do cover. Patients who do not meet Medicaid criteria but cannot afford $580/month should ask their prescriber about the Amgen patient assistance program, described in detail below.

Which Private Insurance Plans Cover Repatha in Hawaii?

Coverage depends heavily on the specific formulary tier your plan uses. Hawaii's largest commercial carriers, including HMSA (the Hawaii Medical Service Association, affiliated with Blue Cross Blue Shield), Kaiser Permanente Hawaii, and UHA Health Insurance, each maintain their own drug formularies that are updated annually.

HMSA typically places evolocumab on a specialty tier requiring prior authorization, a documented statin intolerance or LDL-C threshold above 100 mg/dL in high-risk patients, and evidence of a trial of at least one maximally tolerated statin plus ezetimibe. Kaiser Permanente Hawaii integrates the prescribing and dispensing workflow, so prior authorization is handled within the system, but the LDL-C and statin-trial requirements are similarly stringent.

The FDA-approved label for Repatha specifies its indications as adults with primary hyperlipidemia to reduce LDL-C and adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization [6]. Insurers use this label language to anchor their coverage criteria. If a patient's chart documents a prior MI, stroke, or peripheral artery disease along with LDL-C above 70 mg/dL on statin plus ezetimibe, prior authorization approval rates improve substantially.

Out-of-pocket costs after insurance approval range from $0 (with the Amgen savings card stacked on top of commercial insurance) to several hundred dollars per month on high-deductible plans. Patients on UnitedHealthcare commercial plans in Hawaii may find evolocumab on Tier 4 or 5, with cost-sharing of 20 to 30% coinsurance after the deductible is met [7].

How Does the Amgen Repatha Savings Card Work for Hawaii Patients?

Eligible commercially insured Hawaii patients can pay as little as $0 per month through the Amgen Repatha Copay Card program. Patients who are not covered by a government plan (Medicare, Medicaid, TRICARE, or any federally funded program) and who have commercial insurance may enroll online at Amgen's patient support site or through their prescriber's office.

The mechanics: Amgen subsidizes the gap between what insurance pays and what the patient owes, up to a defined annual maximum. In prior program years, Amgen has capped the annual benefit at $4,800 per year for commercially insured enrollees. Patients pay the first $5 per fill, and Amgen covers the rest of the copay or coinsurance up to the program limit [8].

Hawaii patients using mail-order pharmacy (HMSA members often use Express Scripts; Kaiser uses its own mail-order system) can apply the savings card the same way as at retail. The card is not transferable to Medicaid or Medicare beneficiaries. Patients who lose commercial coverage mid-year should contact Amgen's patient support line immediately, as the benefit resets on a calendar-year basis.

Is Compounded Evolocumab Legal in Hawaii?

Yes. Compounded evolocumab prepared by a state-licensed 503A compounding pharmacy is legal in Hawaii under current federal and state pharmacy law. A 503A pharmacy compounds medication for an individual patient pursuant to a valid prescription from a licensed practitioner [9]. This is distinct from 503B outsourcing facilities, which compound in bulk without patient-specific prescriptions.

The legal basis matters. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding of commercially available drugs when there is a specific patient need that the commercial product does not address, such as cost or a documented allergy to an excipient. Hawaii's Board of Pharmacy enforces state-level compounding regulations that align with USP Chapter 797 sterile compounding standards [10]. Evolocumab is a biologic (a fully human monoclonal antibody), and compounding biologics involves additional technical complexity compared to small-molecule drugs.

Compounded evolocumab from a licensed 503A pharmacy can be substantially cheaper than brand-name Repatha, though prices vary by pharmacy, lot cost, and dispensing fee. Patients should confirm that the compounding pharmacy holds an active Hawaii permit and maintains USP 797 sterile compounding compliance before filling any injectable peptide or biologic preparation. A prescribing clinician should also confirm potency and sterility testing documentation.

It is worth stating clearly: the FDA has not approved any compounded version of evolocumab. The branded product has a defined safety and efficacy record from large trials. Compounded formulations have not undergone the same regulatory review [11].

What Is the Clinical Evidence Behind Evolocumab?

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established ASCVD and LDL-C of at least 70 mg/dL on optimized statin therapy. Published in the New England Journal of Medicine in 2017, FOURIER showed that evolocumab reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative to placebo (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median follow-up of 26 months [12].

LDL-C fell from a median baseline of 92 mg/dL to 30 mg/dL in the evolocumab group, a 59% reduction from baseline [12]. The FOURIER-OLE (open-label extension) followed a subset of patients for up to 8.4 years and found sustained LDL-C reduction with no new safety signals [13].

The GLAGOV trial used intravascular ultrasound to show that evolocumab produced regression of coronary atherosclerosis (change in percent atheroma volume: minus 0.95% with evolocumab vs. plus 0.05% with placebo; P<0.001) in 968 statin-treated patients over 76 weeks [14]. That plaque regression data, published in JAMA in 2016, gave clinicians mechanistic confidence in the LDL-lowering strategy.

For patients with heterozygous familial hypercholesterolemia, the RUTHERFORD-2 trial (N=329) demonstrated a 59.2% mean reduction in LDL-C with evolocumab 140 mg every 2 weeks vs. placebo at week 12 (P<0.001) [15]. For homozygous FH, the TESLA Part B trial (N=49) showed a 30.9% mean LDL-C reduction (P<0.001) [16].

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "For patients with established ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy plus ezetimibe, PCSK9 inhibitor therapy is recommended" [17].

How to Get Repatha via Telehealth in Hawaii

Hawaii permits telehealth prescribing of non-controlled medications, including evolocumab, for established or new patient relationships conducted via synchronous audio-video visits [18]. The Hawaii Telehealth Act (HRS Chapter 453) aligns with federal telehealth flexibilities that allow prescribers licensed in Hawaii to order evolocumab after a documented clinical evaluation, review of lipid panel results, and confirmation of prior statin therapy.

Neighbor island residents on Maui, Kauai, Molokai, Lanai, and the Big Island have historically faced access challenges for specialist cardiology or endocrinology care. Telehealth closes that gap directly. A patient on Lanai with a recent LDL-C of 110 mg/dL despite atorvastatin 40 mg plus ezetimibe 10 mg can receive a telehealth evaluation, a Repatha prescription, and a savings card enrollment within a single visit.

HealthRX clinicians licensed in Hawaii can prescribe evolocumab via telehealth. After the initial visit, lab monitoring (fasting lipid panel at 4 to 8 weeks after initiation, then every 3 to 12 months) can be coordinated through local labs such as Clinical Laboratories of Hawaii or via Quest Diagnostics locations statewide [19].

What Are the Cheapest Ways to Get Repatha in Hawaii?

Ranked by expected out-of-pocket cost for a Hawaii patient in 2026:

Option 1: Commercial insurance plus Amgen savings card. Expected cost: $0 to $5 per month for eligible patients. This combination is the most cost-effective path for commercially insured patients who meet prior authorization criteria.

Option 2: Amgen patient assistance program (PAP). For uninsured or underinsured patients who meet income criteria (household income below 600% of the federal poverty level in some program years), Amgen may provide Repatha at no cost. Applications require proof of income and a prescriber signature [20].

Option 3: Compounded evolocumab from a licensed Hawaii 503A pharmacy. Cash cost varies by pharmacy. Patients should request itemized pricing including the dispensing fee, compounding fee, and any required supplies (syringes, alcohol swabs, cold-pack shipping).

Option 4: GoodRx or pharmacy discount cards. GoodRx prices for brand-name Repatha in Hawaii hover near the $580 WAC because no generic exists. Discount cards offer minimal savings on biologics with no generic competition [21].

Option 5: Switching drug class. If cost remains prohibitive, clinicians may consider inclisiran (Leqvio), a PCSK9 inhibitor given by a clinician in-office twice yearly after the initial dose, which shifts the dispensing cost to the medical benefit rather than the pharmacy benefit and may have different insurance tier placement [22]. Bempedoic acid (Nexletol) at $10 to $30 per month on some formularies is another oral option, though its LDL-C lowering of approximately 18% is smaller than evolocumab's [23].

Monitoring and Safety Considerations for Hawaii Patients

Evolocumab is generally well tolerated. In FOURIER (N=27,564), the incidence of adverse events was similar between the evolocumab and placebo arms [12]. Injection-site reactions occurred in 2.1% of evolocumab patients vs. 1.6% of placebo patients. No signal of new-onset diabetes emerged, which contrasts with high-dose statins [24].

The FDA label requires no routine laboratory monitoring specific to evolocumab beyond standard lipid panel follow-up [6]. Patients should store the autoinjector at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Hawaii's ambient temperatures, particularly on the Big Island and in Maui County, require patients to transport injections in insulated bags when traveling. Leaving the autoinjector at room temperature for up to 30 days (below 77 degrees Fahrenheit) is permitted per the label, but repeated or prolonged heat exposure degrades the biologic [6].

Clinicians prescribing evolocumab to women of childbearing potential should note that FOURIER excluded pregnant patients. Animal studies did not show harm at doses up to 12 times the human dose, but human pregnancy data are limited [6]. The decision to continue evolocumab during pregnancy should involve shared decision-making, documented in the chart [25].

Drug interactions are minimal. Evolocumab does not use cytochrome P450 metabolism. Concomitant statin use (present in over 99% of FOURIER participants) is both safe and expected [12].

Hawaii-Specific Access Considerations

Hawaii's geography creates unique access dynamics. Mail-order pharmacy is practical for most patients, and cold-chain shipping to all major Hawaii islands from mainland fulfillment centers is established for biologic medications. FedEx and UPS both operate temperature-controlled pharmaceutical shipping lanes to Hawaii. Patients in very remote areas (Hana, Maui; Na Pali coast, Kauai) should plan for 2 to 3 business days of transit time and confirm that cold-pack packaging is included in their order.

Hawaii's uninsured rate (approximately 4.2% as of 2023, well below the national average of 7.7% [26]) means most Hawaii residents have some insurance coverage, but the Medicaid exclusion for Repatha disproportionately affects Native Hawaiian and Pacific Islander populations, who have higher rates of ASCVD risk factors including diabetes and hypertension [27]. Clinicians serving these populations may need to be especially proactive about prior authorization appeals or alternative regimens.

The Hawaii Department of Health does not operate a state-specific drug assistance program for Repatha as of 2026. The closest state-level resource is the Rx Outreach program, a national nonprofit that serves Hawaii residents and covers a limited formulary of cardiovascular drugs, though evolocumab is not currently on its list [28].